← Back to Search

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

Valbenazine for Huntington's Disease

Phase 3
Waitlist Available
Research Sponsored by Neurocrine Biosciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to week 106
Awards & highlights

Study Summary

This trial will look at how safe and well-tolerated valbenazine is for people with Huntington Disease who have uncontrollable movements.

Who is the study for?
This trial is for individuals in Canada with Huntington's Disease who experience chorea (involuntary movements) and were part of a previous study, NBI-98854-HD3006. Specific eligibility details are not provided, but typically participants must meet certain health standards to be included.Check my eligibility
What is being tested?
The focus of this study is on the long-term safety and tolerability of a drug called Valbenazine for patients with chorea due to Huntington's Disease. It extends research from an earlier trial.See study design
What are the potential side effects?
While specific side effects for Valbenazine in this context aren't listed here, common ones may include sleepiness, balance problems, dry mouth, and gastrointestinal issues.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to week 106
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to week 106 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

Trial Design

1Treatment groups
Experimental Treatment
Group I: ValbenazineExperimental Treatment1 Intervention
Capsule, administered orally once daily.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Valbenazine
2018
Completed Phase 4
~880

Find a Location

Who is running the clinical trial?

Neurocrine BiosciencesLead Sponsor
75 Previous Clinical Trials
6,744 Total Patients Enrolled
Clinical Development LeadStudy DirectorNeurocrine Biosciences
24 Previous Clinical Trials
2,570 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are potential participants still able to apply for enrollment in this ongoing research study?

"As per clinicaltrials.gov, this particular research endeavor is not actively seeking participants. It was initially registered on March 1st, 2024, with the latest update recorded on March 8th, 2024. Despite its current inactivity, it's noteworthy that there are currently 33 other ongoing trials welcoming new enrollees."

Answered by AI

What are the potential risks associated with Valbenazine usage in individuals?

"With the trial being in Phase 3, indicating existing efficacy data and robust safety information gathered over multiple evaluations, Valbenazine has been rated a score of 3 for safety by our team at Power."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada
2024. "Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06312189.
All > Huntingtons Disease > Huntington Disease
~5 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top